Yongxiang Xia - Search Results

Year	Number of Results
2002	1
2005	1
2006	1
2007	1
2009	1
2010	1
2011	3
2012	4
2013	2
2014	5
2015	6
2016	2
2017	3
2018	5
2019	8
2020	6
2021	5
2022	11
2023	8
2024	1

1

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.

2

PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.

Li Q, Zhang L, You W, Xu J, Dai J, Hua D, Zhang R, Yao F, Zhou S, Huang W, Dai Y, Zhang Y, Baheti T, Qian X, Pu L, Xu J, Xia Y, Zhang C, Tang J, Wang X. Li Q, et al. Among authors: xia y. Nat Commun. 2022 Dec 12;13(1):7677. doi: 10.1038/s41467-022-35469-x. Nat Commun. 2022. PMID: 36509766 Free PMC article.

3

Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.

Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, Dai J, Yu K, Zhang Y, Baheti T, Pu L, Xu J, Qian X, Zhang C, Xia Y, Dai X, Li Q, Wang X. Zhang L, et al. Among authors: xia y. J Hepatol. 2024 Jan;80(1):82-98. doi: 10.1016/j.jhep.2023.10.006. Epub 2023 Oct 12. J Hepatol. 2024. PMID: 37838036

4

Defective mitophagy in aged macrophages promotes mitochondrial DNA cytosolic leakage to activate STING signaling during liver sterile inflammation.

Zhong W, Rao Z, Xu J, Sun Y, Hu H, Wang P, Xia Y, Pan X, Tang W, Chen Z, Zhou H, Wang X. Zhong W, et al. Among authors: xia y. Aging Cell. 2022 Jun;21(6):e13622. doi: 10.1111/acel.13622. Epub 2022 May 22. Aging Cell. 2022. PMID: 35599014 Free PMC article.

5

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.

Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Xia Y, et al. J Immunother Cancer. 2022 Apr;10(4):e004656. doi: 10.1136/jitc-2022-004656. J Immunother Cancer. 2022. PMID: 35379737 Free PMC article. Clinical Trial.

6

Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma.

Tang W, Sun G, Ji GW, Feng T, Zhang Q, Cao H, Wu W, Zhang X, Liu C, Liu H, Huang T, Liu L, Xia Y, Wang X. Tang W, et al. Among authors: xia y. J Immunother Cancer. 2023 Nov 24;11(11):e007030. doi: 10.1136/jitc-2023-007030. J Immunother Cancer. 2023. PMID: 38007237 Free PMC article.

7

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.

Sun G, Liu H, Zhao J, Zhang J, Huang T, Sun G, Zhao S, Zhang Z, Cao H, Rong D, Kong X, Ji Q, Liu L, Wang X, Tang W, Xia Y. Sun G, et al. Among authors: xia y. J Immunother Cancer. 2022 Dec;10(12):e005655. doi: 10.1136/jitc-2022-005655. J Immunother Cancer. 2022. PMID: 36600662 Free PMC article.

8

The Ninj1/Dusp1 Axis Contributes to Liver Ischemia Reperfusion Injury by Regulating Macrophage Activation and Neutrophil Infiltration.

Hu Y, Zhan F, Wang Y, Wang D, Lu H, Wu C, Xia Y, Meng L, Zhang F, Wang X, Zhou S. Hu Y, et al. Among authors: xia y. Cell Mol Gastroenterol Hepatol. 2023;15(5):1071-1084. doi: 10.1016/j.jcmgh.2023.01.008. Epub 2023 Jan 31. Cell Mol Gastroenterol Hepatol. 2023. PMID: 36731792 Free PMC article.

9

Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.

Lei Z, Ma W, Si A, Zhang Y, Yang F, Yu Q, Tang H, Xiao Q, Zhou J, Wang K, Tang Y, Han T, Yin G, Chen J, Liu X, Zhao H, Yu D, Luo T, Wang Q, Yan M, Mao X, Li J, Wang K, Li J, Zeng Y, Ding D, Chen T, Wu X, Xia Y, Wang K, Guo W, Zhu G, Gao S, Hüser N, Lau WY, Song T, Cheng S, Shen F, Cheng Z. Lei Z, et al. Among authors: xia y. Aliment Pharmacol Ther. 2023 Sep;58(6):611-622. doi: 10.1111/apt.17623. Epub 2023 Jun 22. Aliment Pharmacol Ther. 2023. PMID: 37349908

10

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.

Rong D, Wang Y, Liu L, Cao H, Huang T, Liu H, Hao X, Sun G, Sun G, Zheng Z, Kang J, Xia Y, Chen Z, Tang W, Wang X. Rong D, et al. Among authors: xia y. J Immunother Cancer. 2023 Feb;11(2):e005126. doi: 10.1136/jitc-2022-005126. J Immunother Cancer. 2023. PMID: 36787938 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

68 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year